Research Overview
BPC-157 Capsules are an oral research format of the pentadecapeptide BPC-157, supplied as 30 capsules at 500mcg per capsule. The peptide itself shares the same 15-amino-acid sequence GEPPPGKPADDAGLV, molecular weight 1419.55 g/mol and CAS 137525-51-0 as the lyophilised vial form. What makes the capsule format research-relevant is the route of administration; BPC-157 was originally identified in a partial sequence of a protein found in human gastric juice, which has motivated extensive published work using oral and intragastric administration in rodent models. The capsule preparation is designed for in-vitro and preclinical research where the investigator specifically wants the compound to engage gastrointestinal mucosal tissue, gut-resident receptors, or the brain-gut axis. Because the parent sequence is documented in the literature as relatively stable in the gastric environment, oral research protocols have remained an active area of investigation. Each box supplied by Origin Research contains 30 capsules at 99.3% peptide purity by HPLC, with a batch-specific Certificate of Analysis available on request. The product is intended strictly for in-vitro and preclinical laboratory research use only.
Mechanism Studied in Research
The mechanism investigated in oral BPC-157 research overlaps with the injectable form but places greater emphasis on gastrointestinal and brain-gut axis pathways. BPC-157 oral administration has been investigated in rodent models of gastric injury, colitis and mucosal healing, where researchers have documented interactions involving nitric oxide (NO) signalling, angiogenesis-related pathways and tissue-remodelling processes. Additional studies have examined behavioural and stress-related endpoints following oral administration, with researchers evaluating downstream neurotransmitter activity and gut-derived signalling molecules. The peptide has also been investigated in gastrointestinal ulcer models where maintenance of epithelial integrity and mucosal repair are common experimental endpoints. Although no single receptor mechanism has been conclusively established, published literature continues to evaluate BPC-157 as a compound of interest in gastrointestinal physiology, barrier function and recovery-related biological pathways.
Research Applications
Gastrointestinal mucosal models. The oral capsule format is most commonly used in research designs that examine mucosal integrity following induced injury, including alcohol, NSAID and cysteamine-induced ulcer models. Investigators measure outcomes such as ulcer size, epithelial regeneration markers and prostaglandin-pathway modulation, and the oral route is preferred because it provides direct mucosal contact.
Brain-gut axis research. A distinctive line of work in the BPC-157 literature has examined gut-derived effects on dopaminergic and serotonergic signalling. Oral administration in the preferred route in these models because it engages the gastrointestinal entry point of the brain-gut axis and allows researchers to study downstream CNS-related markers.
Inflammatory bowel research. Oral BPC-157 has been investigated in colitis and inflammatory bowel models, where researchers examine cytokine expression, mucosal repair and tight-junction protein integrity. The oral format is suited to studies where the compound is expected to act locally within the intestinal lumen.
Comparative route research. Because the lyophilised vial form supports parenteral research routes, several published designs have compared oral and injectable administration of BPC-157 in parallel. The capsule format is the practical option for oral-arm investigations and is therefore frequently selected when gastrointestinal-targeted exposure rather than systemic delivery is the primary objective.
Reconstitution Reference
BPC-157 Capsules are an oral research format and do not require reconstitution in the same way as lyophilised vial peptides. Each capsule contains 500mcg of peptide pre-measured for direct use in oral research protocols. No bacteriostatic water, syringe, or dilution steps are needed for the standard oral research route.
A practical research equivalent of 500mcg per capsule means that a 30-capsule box contains a total of 15mg peptide. The capsules are supplied ready for administration within approved laboratory protocols and should be stored in their original packaging until use.
If a researcher protocol requires the peptide to be reformulated into solution, the capsule contents can be opened and dissolved under validated laboratory conditions. Any such preparation should be documented according to the study design and laboratory SOPs.
Storage and Handling
Store BPC-157 Capsules in their original blister or container at 2–8°C, protected from light, moisture and direct heat. Short periods at room temperature during transit are acceptable, but long-term ambient storage is not recommended.
For research timelines beyond 12 months, refrigerated storage is preferred. The capsule shell protects the peptide from environmental exposure, which makes this capsule format more practical for storage than reconstituted solutions.
Keep the container closed when not in use and avoid transferring capsules into unlabelled secondary packaging. Capsules should be inspected before use and any that appear damaged, discoloured or that show signs of moisture damage should be discarded.
References
[2] Sikiric P. et al. (2007). Brain-gut axis and pentadecapeptide BPC-157: theoretical and practical implications. Curr Neuropharmacol.
[3] Chang C.C. et al. (2010). The promoting effect of pentadecapeptide BPC-157 on tendon healing via tendon outgrowth, cell survival and cell migration. J Appl Physiol.
[4] Vukojevic M. et al. (1999). BPC-mediated neurotrophic action and induced colitis damage in rats. J Pharmacol Exp Ther.
[5] Klicek R. et al. (2013). Stable gastric pentadecapeptide BPC-157 in the treatment of colitis and ischemia and reperfusion in rats. J Physiol Pharmacol.